DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
Jamie Freed - 2 Elliott - 1 BioMarin - 1 hemophilia - 1 Jean - 1 Jacques Bienaime - 1 Alexander Hardy - 1 Jefferies - 1
Top related locs:
BioMarin San Rafael , California West Palm Beach , Florida New York California , New York , Illinois Minnesota Washington Wisconsin
Top related orgs:
Alexion Pharma - 2 Thomson - 2 Investment Management - 1 BioMarin Pharmaceutical - 1 Biotechnology - 1 Svea - 1 Federal Trade Commission - 1 Horizon Therapeutics - 1

Search resuls for: "Alexion Pharma"


4 mentions found


☆ Exclusive: Activist investor Elliott targets drugmaker BioMarin -sources
  + stars: | 2023-11-07 | by ( Svea Herbst-Bayliss | ) www.reuters.com   time to read: +3 min
NEW YORK, Nov 7 (Reuters) - Activist investor Elliott Investment Management has built a stake in BioMarin Pharmaceutical (BMRN.O) and has been in discussions with the biotechnology company for months about its future, according to two people familiar with the matter. Elliott declined to comment, while a representative for BioMarin did not immediately respond to a request for comment. BioMarin shares rose 12% to $85.36 on the news in morning trading in New York on Tuesday. Prior to news of Elliott's engagement, BioMarin shares were down 24% year-to-date, significantly underperforming the iShares Biotechnology ETF (IBB.O), which is down 8.6%. Elliott also successfully pushed for drug makers Alexion Pharma (AZN.L) and Allergan (ABBV.N) to be sold.
Persons: Elliott, BioMarin, hemophilia, Jean, Jacques Bienaime, Alexander Hardy, Jefferies, Bienaime, Harvey, Richard Meier, Svea Herbst, Bayliss, Jamie Freed Organizations: Investment Management, BioMarin Pharmaceutical, Biotechnology, Alexion Pharma, Svea, Thomson Locations: BioMarin, San Rafael , California, West Palm Beach , Florida, New York
☆ California, other states join FTC bid to block Amgen deal
  + stars: | 2023-06-22 | by ( David Shepardson | ) www.reuters.com   time to read: +2 min
WASHINGTON, June 22 (Reuters) - The states of California, New York, Illinois, Minnesota, Washington and Wisconsin have joined a Federal Trade Commission (FTC) lawsuit to stop Amgen's (AMGN.O) $27.8 billion deal to buy Horizon Therapeutics (HZNP.O), according to a court filing on Thursday. Washington Attorney General Bob Ferguson said his state had joined the lawsuit because "monopolies harm consumers" and the merger could allow Amgen to "dominate" prescription drug markets. The FTC acquisition marks a change for the agency, which previously had typically flagged therapeutic overlaps in companies and waved deals through after requiring one of the medicines to be divested. Amgen said in a statement last month it was disappointed by the FTC decision and it believed it had "overwhelmingly demonstrated" that the deal had no legitimate competitive issues. The last major pharmaceutical deal approved by the FTC was AstraZeneca's (AZN.L) $39 billion acquisition of Alexion Pharma in April 2021, about two months before FTC Chair Lina Khan was appointed by the Biden administration.
Persons: Bob Ferguson, Rob Bonta, Amgen, Lina Khan, Biden, David Shepardson, Jamie Freed Organizations: Federal Trade Commission, Horizon Therapeutics, . Washington, FTC, Horizon, Alexion Pharma, Thomson Locations: California , New York , Illinois, Minnesota, Washington, Wisconsin, California
☆ Why biotech CEOs are growing more cautious about going public — and what they're waiting for
  + stars: | 2023-01-30 | by ( Andrew Dunn | Yeji Jesse Lee | ) www.businessinsider.com   time to read: +6 min
Biotech-startup CEOs are taking more nuanced approaches to going public amid a downturn. SAN FRANCISCO — After record years of initial public offerings in 2020 and 2021, biotech leaders told Insider that the "recipe" for going public no longer works. Most biotechs saw their valuations increase by between 20% and 50% after going public. Insider asked five startup CEOs about how they approach going public and their perspectives on the biotech-IPO market for 2023. But going public doesn't carry an importance of validation for herself or the field of biotech companies specializing in AI, she said.
☆ The recipe biotech startups use to go public is being thrown out. 5 startups CEOs reveal how they're changing their focus.
  + stars: | 2023-01-26 | by ( Andrew Dunn | Yeji Jesse Lee | ) www.businessinsider.com   time to read: +6 min
Biotech-startup CEOs are taking more nuanced approaches to going public amid a downturn. SAN FRANCISCO — After record years of initial public offerings in 2020 and 2021, biotech leaders told Insider that the "recipe" for going public no longer works. Most biotechs saw their valuations increase by between 20% and 50% after going public. Insider asked five startup CEOs about how they approach going public and their perspectives on the biotech-IPO market for 2023. But going public doesn't carry an importance of validation for herself or the field of biotech companies specializing in AI, she said.
0 next >>
Total: 4